Lipomatous Neometaplasia of the Uterus. Report of 11 Cases with Discussion of Histogenesis and Pathogenesis

article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-08

This study examined 11 uterine lipomatous neometaplasia cases, finding lipoleiomyomas and angiolipoleiomyomas, and proposing that they originate from pericapillary mesenchymal cells differentiating within leiomyomas.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Eleven cases of uterine lipomatous neometaplasia were studied. The patients ranged in age from 41 to 74 years (mean, 56.6 years). There were eight lipoleiomyomas and 3 angiolipoleiomyomas. In eight tumors the lipomatous component consisted only of mature lipocytes. In three tumors, pericapillary differentiating lipocytes also occurred. No correlation between the proportion of the lipomatous and leiomyomatous components and the size of tumor was observed. There was also no correlation between the amount and distribution of the lipomatous component and the hyalinized fibrous stroma. The levels of cytosolic estrogen and progesterone receptors, studied in one case, were lower in the lipoleiomyoma than in the myometrium. Leiomyomas and adenomyosis were the most frequent accompanying lesions. The study supports a notion that uterine lipomatous neometaplasia originates from pericapillary pluripotential mesenchymal cells. Present findings suggest that lipomatous differentiation of immature neoplastic cells can occur in a preexisting leiomyoma, as well as simultaneously with leiomyomatous differentiation.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Leiomyoma Uterine Neoplasms Uterus Adult Aged Female Humans Leiomyoma Leiomyoma Leiomyoma Metaplasia Metaplasia Metaplasia Middle Aged Myometrium Myometrium Myometrium Receptors, Estrogen Receptors, Estrogen Receptors, Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (7)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK